SCHEMBL21887930

SCHEMBL21887930

CC1(C)c2ccccc2-c2cc(C3(c4ccccc4)c4ccccc4Nc4ccccc43)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.45
MAPT P10636 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
OPRK1 P41145 1/20 0.44
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
XBP1 P17861 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CHRM2 P08172 2/20 0.38
KCNH2 Q12809 2/20 0.38
ADORA3 P0DMS8 1/20 0.38
PDK2 Q15119 2/20 0.37
PDK4 Q16654 1/20 0.37
POLB P06746 1/20 0.33
PGR P06401 1/20 0.31
HTR5A P47898 2/20 0.31
KIF11 P52732 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21887915 0.91 LMNA (0.45) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL31757120 0.85 ESR1 (0.44) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL31757119 0.85 ESR1 (0.46) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL21888804 0.81 MAPT (0.42) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL26157463 0.81 MEN1 (0.46) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL21887921 0.81 POLB (0.44) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL23335626 0.78 LMNA (0.41) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL25937157 0.78 LMNA (0.52) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL21585374 0.77 PDK2 (0.40) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL29373003 0.77 LMNA (0.69) LMNAMAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11158814-B2 9,10-dihydro-acridine derivative, and preparation method and use thereof NINGBO LUMILAN ADVANCED MATERIALS CO., LTD (CN) 2021-10-26 US disclosed
WO-2020056860-A1 9,10-DIHYDROACRIDINE DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF 宁波卢米蓝新材料有限公司 2020-03-26 WO disclosed
WO-2020056859-A1 9,10-DIHYDROACRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 宁波卢米蓝新材料有限公司 2020-03-26 WO disclosed
US-20200091436-A1 9,10-DIHYDRO-ACRIDINE DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF NINGBO LUMILAN ADVANCED MATERIALS CO., LTD. (CN) 2020-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11158814-B2 9,10-dihydro-acridine derivative, and preparation method and use thereof GAPVD1, DHX9, DHRS9 LMNA 535/4885MAPT 526/4885MEN1 4288/4885
US-20200091436-A1 9,10-DIHYDRO-ACRIDINE DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF DHODH, DHRS9, QDPR LMNA 1105/4885MAPT 740/4885MEN1 4830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.